QualityDipStocks / Real Estate · REITs
Medical Properties Trust common stock MPT
Outside our quality screen, so we don’t track its dips. It’s 64% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
Worth knowing
- Lowest price in 5 years of weekly closes
- Down 66% from its 52-week high while revenue grew 11%
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −64%
- Risk vs market
- Lowbeta 0.65
52-week range at its 52-week low
Price $2.18
5 bullish · 5 bearish See why
Repriced or dip?
Mixed signals
The price is 64% below its 52-week high (Feb 19), but the business held up: revenue +9.2%, shares outstanding fewer shares, each owns more.
Some numbers held up (revenue +9.2%, shares outstanding fewer shares, each owns more), others slipped (revenue growth rate −35.0 pts, net cash (cash minus debt) −6.8% of market cap since the high). The price is 64% below its 52-week high.
The price is 64% below its 52-week high, and the business changed too: revenue growth rate −35.0 pts, net cash (cash minus debt) −6.8% of market cap since the high.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 6 numbers, high vs now
- Revenue, last 12 months$934M → $1.0B (+9.2%)held up
- Revenue growth rate+45.6% → +10.6% a year (−35.0 pts)changed
- Shares outstanding−0.8% (fewer shares, each owns more)held up
- Net cash (cash minus debt)−6.8% of market cap since the highchanged
- Stock vs its sector (Real Estate)stock −64%, sector median +1% since Feb 19changed
- Price fall vs business numbersprice −64%, revenue/EPS/FCF median +9% (shown, not scored)
Business numbers as reported at the high (12 months to Sep 30, 2025) vs the latest filing (12 months to Jun 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for MPT: Capital spending isn't tagged in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much MPT moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 3.1× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.65
- Volatility
- 40% vs 13% SPY
- Correlation SPY
- 0.21
- Correlation QQQ
- 0.15
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
Cash returnsDividend yield of 15.9% ($206M paid over 12 months).
ProfitabilityGross margin widened to 90.7% in FY2025 from 87.4% in FY2023 (SEC filings).
GrowthSales grew 11% to $1.0B over the last 12 months vs the 12 months before (SEC filings).
ValuationPrice / book of 0.3×, below the 1.8× median for the 105 Real Estate companies we cover.
TechnicalRSI(14) of 18: oversold, the zone where our reversal signal rules start watching.
Top bearish points 5 of 5
ProfitabilityLost $30M over the last 12 months (net income, SEC filings).
Balance sheetNet debt of $9.3B, 716% of the market cap (Jun 30, 2026).
GrowthSales shrank 14% a year from FY2022 to FY2025.
Balance sheetDebt is 2.2× shareholders’ equity.
QualityDoesn’t pass our quality screen: no cash-flow data; ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter; net debt 9.2× EBITDA (limit 3×).
All fundamentals
ROE -1% · Sales +11%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 1.28×
- Price / book
- 0.29×
- Market cap
- $1.3Blisted
- Enterprise value
- $10.6B
Growth
- Revenue, 12 months
- $1.0B
- Sales growth, 12 months
- +10.6%vs the 12 months before
- Sales growth, 3 yrs
- −14.3%/yrfrom FY2022
- Diluted EPS, 12 months
- n/anot reported in its SEC filings
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$30M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 90.3%
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- −3.0%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- −1%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $397M
- Total debt
- $9.7B
- Net cash
- −$9.3B
- Debt / equity
- 2.16×
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 15.87%$206M paid
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $30M2.3% of market cap
- Share count, 1 year
- −0.5%diluted shares vs a year ago
- Stock-based comp
- $13M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Medical Properties Trust common stock’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
Sales −5%
- Gross margin96%
- Operating margin57%
- Return on invested capital4%
- Return on equity5%
- Sales growth (latest quarter vs year-ago quarter)−5%
- Net debt / EBITDA9.2×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $2.18
- PriceMon Nov 2 close$2.18you are here
- 52-wk lowlowest close, 1 year$2.18at the price
- 52-wk highhighest close, 1 year$6.02+176.1%
Momentum & 52-week range
RSI 18 · 5 days −22.1%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
MPT is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Medical Properties Trust common stock in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in REITs
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.